Not yet recruiting
Stargardt's disease
Not yet recruitingPhase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults
Investigational
Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults
Investigational
- Disease:Stargardt's disease
- Substances:Gildeuretinol acetate
Countries:
Belgium
Belgium- Participants:0–17 years · 18–64 years
- Substances:Gildeuretinol acetate



